SCHEMBL839591

SCHEMBL839591

COC[C@@H](O)C(=O)Nc1ccc(C)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.55
MAPT P10636 1/20 0.55
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 6/20 0.45
TP53 P04637 2/20 0.45
GAA P10253 2/20 0.45
MITF O75030 1/20 0.45
GCK P35557 2/20 0.45
KCNH2 Q12809 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RXFP1 Q9HBX9 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ADRA2A P08913 2/20 0.44
ADRA2B P18089 2/20 0.44
ADRA2C P18825 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839502 1.00 RAB9A (0.55) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL838748 1.00 RAB9A (0.55) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL839929 0.90 RAB9A (0.48) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL839930 0.90 RAB9A (0.48) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL838343 0.89 RAB9A (0.53) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL838342 0.89 RAB9A (0.53) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL838720 0.86 RAB9A (0.53) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL838265 0.86 RAB9A (0.53) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL838266 0.86 RAB9A (0.53) RAB9AMAPTKMT2AMEN1KDM4E
SCHEMBL839483 0.86 RAB9A (0.53) RAB9AMAPTKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 RAB9A 3239/4885MAPT 3944/4885KMT2A 4136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.